Formulation Development Strategy for Early Phase Human Studies

ASC-Blog_Thumb-2026-11-FormulationForum

“FORMULATION FORUM – Formulation Development Strategy for Early Phase Human Studies,” by Jim Huang, PhD, Founder of Ascendia Pharmaceutical Solutions, in the September 2020 issue of Drug Development and Delivery.

The article argues that moving discovery compounds into first-in-human (Phase 1) and first-in-patient (Phase 2) studies is a major challenge for the industry. A rational, phase-appropriate formulation strategy is needed to avoid costly failures and to speed development cost-effectively, especially for poorly soluble or poorly bioavailable compounds.

At this stage, API supply is limited, and it is hard to pick a bioavailable formulation for animal PK, GLP toxicity, and human studies. The recommended starting point is pre-formulation work: checking solubility and stability in common solvents and biorelevant media, measuring permeability, and then screening delivery systems. Simple formulations such as solutions, suspensions, and drug-in-capsule are preferred for speed, but adequate systemic exposure comes first.

Formulation choice depends on several factors. Route, dose, and solubility decide between a solution and a suspension. Dose flexibility matters because the maximum tolerated human dose is not yet known. Blinding is another factor: taste or color differences between active and placebo have to be managed. So is where dosing happens, because in-hospital and outpatient dosing have different shelf-life and storage needs.

The article describes four dosage-form options:

  • Drug-in-bottle. The API is reconstituted at a hospital pharmacy, which gives dose flexibility and requires minimal stability data.
  • Ready-to-use solution or suspension. This suits outpatient dosing when the compound is stable for at least 3 to 6 months.
  • Drug-in-capsule. This works when the API wets and dissolves readily in GI fluids without excipients, and it suits blinded studies.
  • Formulated capsule or tablet. This suits chronic dosing or a fast move to late phase, and it can include enabling technologies such as nanosuspensions, lipid systems and amorphous solid dispersions. 

The article also names Ascendia Pharmaceutical Solutions' AmorSol®, NanoSol® and EmulSol® platforms.

Frequently Asked Questions

Q: What is a phase-appropriate formulation strategy?

It is a formulation approach matched to the needs of the current clinical stage rather than to the final commercial product. For Phase 1 and 2, the formulation has to deliver adequate systemic exposure, allow flexible dosing, fit the study design (such as blinding) and keep to tight timelines, all while API supply is limited.

Q: Why is formulation strategy critical for first-in-human studies?

A poorly chosen formulation can give inadequate drug exposure. A compound can then fail in Phase 1 or later because the formulation didn’t work, not because the molecule was flawed. A rational strategy reduces costly failures and speeds the path to the clinic. This matters most for poorly soluble or poorly bioavailable compounds.

Q: What pre-formulation studies should be done before early-phase clinical trials?

Solubility and stability testing in common solvents and biorelevant media, permeability assessment, and screening of delivery systems to improve solubility and bioavailability. These results guide the formulation used for animal PK, GLP toxicology, and human dosing.

Q: What dosage forms are commonly used in Phase 1 clinical trials?

There are four main options:

  • Drug-in-bottle, reconstituted at the pharmacy
  • Ready-to-use oral solutions or suspensions
  • Drug-in-capsule, which is API alone in a hard capsule
  • Formulated capsules or tablets

Simple forms are preferred for speed, as long as they give enough exposure.

Q: When should you use drug-in-bottle versus drug-in-capsule?

Drug-in-bottle suits in-hospital dosing where dose flexibility is needed, and stability data are limited. Drug-in-capsule suits outpatient and blinded studies when the API wets and dissolves well in GI fluids without excipients.

Q: How do you choose between a solution and a suspension for early clinical studies?

The route, the dose requirement, and the compound’s solubility decide it. If both are used across studies, a biopharmaceutical bridging assessment is needed, and each form needs its own stability data and handling instructions.

Q: How are placebo-controlled blinded studies handled in early-phase formulation?

Taste and appearance differences between active and placebo have to be masked. For liquids, this can mean bittering agents. Other options are colored packaging, syringes, or dosing cups. Pediatric studies may also need taste masking.

Q: What enabling technologies help poorly soluble drugs reach the clinic?

Amorphous solid dispersions, nanosuspensions, and lipid-based systems such as SEDDS and nanoemulsions. Ascendia Pharmaceuticals’ platforms for these are AmorSol®, NanoSol®, and EmulSol®.

Q: How does outpatient dosing affect formulation choice?

Outpatient studies need longer shelf life and simple storage. Ready-to-use liquids stored at room temperature or refrigerated, or capsules, are usually preferred over pharmacy-reconstituted products.